Regulation of the differentiation and function of osteoclasts, The Journal of Pathology, vol.401, issue.1, pp.4-13, 2000. ,
DOI : 10.1002/1096-9896(2000)9999:9999<::AID-PATH645>3.0.CO;2-Q
Regulation of Osteoclast Differentiation, Annals of the New York Academy of Sciences, vol.102, issue.1, pp.100-109, 2006. ,
DOI : 10.1210/en.133.1.397
Correlation of Bone Resorption and Formation with the Physical Behavior of Loaded Bone, Journal of Dental Research, vol.44, issue.1, pp.33-41, 1965. ,
DOI : 10.1177/00220345650440012801
Gap-Junctional Regulation of Osteoclast Function, Critical Reviews in Eukaryotic Gene Expression, vol.13, issue.2-4, pp.133-146, 2003. ,
DOI : 10.1615/CritRevEukaryotGeneExpr.v13.i24.70
CYTOKINES, GROWTH FACTORS AND OSTEOCLASTS, Cytokine, vol.10, issue.3, pp.155-168, 1998. ,
DOI : 10.1006/cyto.1997.0277
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling, Cytokine & Growth Factor Reviews, vol.15, issue.6, pp.457-475, 2004. ,
DOI : 10.1016/j.cytogfr.2004.06.004
A New Member of Tumor Necrosis Factor Ligand Family, ODF/OPGL/TRANCE/RANKL, Regulates Osteoclast Differentiation and Function, Biochemical and Biophysical Research Communications, vol.256, issue.3, pp.449-455, 1999. ,
DOI : 10.1006/bbrc.1999.0252
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proceedings of the National Academy of Sciences, vol.95, issue.7, pp.3597-3602, 1998. ,
DOI : 10.1073/pnas.95.7.3597
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation, Cell, vol.93, issue.2, pp.165-176, 1998. ,
DOI : 10.1016/S0092-8674(00)81569-X
URL : http://doi.org/10.1016/s0092-8674(00)81569-x
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, vol.397, pp.315-323, 1999. ,
TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells, Journal of Biological Chemistry, vol.272, issue.40, pp.25190-25194, 1997. ,
DOI : 10.1074/jbc.272.40.25190
Key roles of the OPG-RANK-RANKL system in bone oncology, Expert Rev Anticancer Ther, vol.7, pp.221-232, 2007. ,
Osteoclast differentiation and activation, Nature, vol.34, issue.6937, pp.337-342, 2003. ,
DOI : 10.1007/s007740200049
Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities, Experimental Cell Research, vol.293, issue.2, pp.292-301, 2004. ,
DOI : 10.1016/j.yexcr.2003.10.016
Osteoclast signalling pathways, Osteoclast signalling pathways, pp.728-738, 2005. ,
DOI : 10.1016/j.bbrc.2004.11.077
Involvement of p38 Mitogen-activated Protein Kinase Signaling Pathway in Osteoclastogenesis Mediated by Receptor Activator of NF-??B Ligand (RANKL), Journal of Biological Chemistry, vol.275, issue.40, pp.31155-31161, 2000. ,
DOI : 10.1074/jbc.M001229200
The phosphatidylinositol 3-Kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation, Bone, vol.30, issue.1, pp.71-77, 2002. ,
DOI : 10.1016/S8756-3282(01)00657-3
Wortmannin, a potent inhibitor of phosphatidylinositol 3-kinase, inhibits osteoclastic bone resorption in vitro, Calcified Tissue International, vol.64, issue.4, pp.336-338, 1995. ,
DOI : 10.1007/BF00318056
Wortmannin, a specific inhibitor of phosphatidylinositol-3 kinase, blocks osteoclastic bone resorption, FEBS Letters, vol.267, issue.1, pp.79-84, 1995. ,
DOI : 10.1016/0014-5793(95)00153-Z
Novel neurotrophin-1/B cell-stimulating factor-3: A cytokine of the IL-6 family, Proceedings of the National Academy of Sciences, vol.96, issue.20, pp.11458-11463, 1999. ,
DOI : 10.1073/pnas.96.20.11458
Principles of interleukin (IL)-6-type cytokine signalling and its regulation, Biochemical Journal, vol.374, issue.1, pp.1-20, 2003. ,
DOI : 10.1042/bj20030407
Interleukin-6 family of cytokines and gp130, Blood, vol.86, pp.1243-1254, 1995. ,
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma, Oncogene, vol.20, issue.42, pp.5991-6000, 2001. ,
DOI : 10.1038/sj.onc.1204833
Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis, N Engl J Med, vol.332, pp.305-311, 1995. ,
17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens., Journal of Clinical Investigation, vol.89, issue.3, pp.883-891 ,
DOI : 10.1172/JCI115668
Studies in Paget's disease and their relevance to oncology, Seminars in Oncology, vol.28, issue.11, pp.15-21, 2001. ,
DOI : 10.1016/S0093-7754(01)90227-1
Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma, Eur Cytokine Net, vol.1, pp.193-201, 1990. ,
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation, Journal of Bone and Mineral Research, vol.152, issue.suppl, pp.88-95, 1996. ,
DOI : 10.1002/jbmr.5650110113
Circulating levels of interleukin-6 and tumor necrosis factor-are elevated in primary hyperparathyroidism and correlate with markers of bone resorption?a clinical research center study, J Clin Endocrinol Metab, vol.81, pp.3450-3454, 1996. ,
gp130 CYTOKINE FAMILY AND BONE CELLS, Cytokine, vol.12, issue.10, pp.1455-1468, 2000. ,
DOI : 10.1006/cyto.2000.0747
Osteoclasts are not the major source of interleukin-6 in mouse parietal bones, Bone, vol.18, issue.3, pp.221-226, 1996. ,
DOI : 10.1016/8756-3282(95)00482-3
IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-??B Ligand, Osteoprotegerin, and Receptor Activator of NF-??B in Mouse Calvariae, The Journal of Immunology, vol.169, issue.6, pp.3353-3362, 2002. ,
DOI : 10.4049/jimmunol.169.6.3353
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes, Genome Biol, vol.3, p.34, 2002. ,
Functional Interaction of STAT3 Transcription Factor with the Cell Cycle Inhibitor p21WAF1/CIP1/SDI1, Journal of Biological Chemistry, vol.275, issue.25, pp.18794-18800, 2000. ,
DOI : 10.1074/jbc.M001601200
MafB negatively regulates RANKL-mediated osteoclast differentiation, Blood, vol.109, issue.8, pp.3253-3259, 2007. ,
DOI : 10.1182/blood-2006-09-048249
U0126 and PD98059, Specific Inhibitors of MEK, Accelerate Differentiation of RAW264.7 Cells into Osteoclast-like Cells, Journal of Biological Chemistry, vol.277, issue.49, pp.47366-47372, 2002. ,
DOI : 10.1074/jbc.M208284200
Tracking STAT nuclear traffic, Nature Reviews Immunology, vol.16, issue.8, pp.602-612, 2006. ,
DOI : 10.1038/nri1885
STATs and gene regulation, Science, vol.277, pp.1630-1635, 1997. ,
Osteoporosis with increased osteoclastogenesis in hematopoietic cell-specific STAT3-deficient mice, Biochemical and Biophysical Research Communications, vol.328, issue.3, pp.800-807, 2005. ,
DOI : 10.1016/j.bbrc.2005.01.019
Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways, Journal of Clinical Investigation, vol.113, issue.3, pp.379-389, 2004. ,
DOI : 10.1172/JCI19872
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC324544
Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome, Nature, vol.286, issue.7157, pp.1058-1062, 2007. ,
DOI : 10.1038/nature06096
Mutations in the Hyper-IgE Syndrome, STAT3 mutations in the hyper-IgE syndrome, pp.1608-1619, 2007. ,
DOI : 10.1056/NEJMoa073687
Hyper-IgE Syndrome with Recurrent Infections ??? An Autosomal Dominant Multisystem Disorder, New England Journal of Medicine, vol.340, issue.9, pp.692-702, 1999. ,
DOI : 10.1056/NEJM199903043400904
Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival, Blood, vol.102, issue.1, pp.344-352, 2003. ,
DOI : 10.1182/blood-2002-11-3396
Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation, FEBS Letters, vol.21, issue.1-2, pp.71-76, 2001. ,
DOI : 10.1016/S0014-5793(01)02354-7
Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylation, Cell, vol.82, issue.2, pp.241-250, 1995. ,
DOI : 10.1016/0092-8674(95)90311-9
Insulin Stimulates the Serine Phosphorylation of the Signal Transducer and Activator of Transcription (STAT3) Isoform, Journal of Biological Chemistry, vol.271, issue.21, pp.12121-12124, 1996. ,
DOI : 10.1074/jbc.271.21.12121
Serine Phosphorylation and Negative Regulation of Stat3 by JNK, Journal of Biological Chemistry, vol.274, issue.43, pp.31055-31061, 1999. ,
DOI : 10.1074/jbc.274.43.31055
STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation., Molecular and Cellular Biology, vol.17, issue.11, pp.6508-6516 ,
DOI : 10.1128/MCB.17.11.6508
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC232504
Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK), Oncogene, vol.17, issue.24, pp.3157-3167 ,
DOI : 10.1038/sj.onc.1202238
STAT3 as a Downstream Mediator of Trk Signaling and Functions, Journal of Biological Chemistry, vol.281, issue.23, pp.15636-15644, 2006. ,
DOI : 10.1074/jbc.M601863200
Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NF??B, Genes & Development, vol.21, issue.11, pp.1396-1408, 2007. ,
DOI : 10.1101/gad.1553707
IL-1: interrelations in bone resorption pathophysiology, Cytokine Growth Factor Rev, vol.15, pp.49-60, 2004. ,